Table of Content


Spring 2020, Vol. 28 No. 1

Hong Kong J. Dermatol. Venereol. (2020) 28, 11-16

Review Article

Cutaneous adverse effects of targeted therapies


OC Lau 劉安祥


Novel antineoplastic therapy has evolved and shifted to molecularly targeted agents. They are designed to block specific cancer cell processes. However, many of these agents, particularly those interfering with signal transduction (e.g., epidermal growth factor receptor [EGFR] inhibitors, multitargeted tyrosine kinase inhibitors [TKIs]), frequently cause cutaneous adverse events. The dermatological adverse reactions not only affect cosmetically, but may also lead to poor treatment adherence, dose reduction or even discontinuation of treatment. In this article, we will describe key clinical features of common dermatological adverse reactions among the common targeted therapies, focusing mainly on skin toxicity, as well as to discuss the pathology and suggested treatments for these reactions.


Keywords: Cutaneous adverse reaction, epidermal growth factor inhibitors, multi-targeted tyrosine kinase inhibitors, targeted therapy

關鍵詞: 皮膚不良反應、表皮生長因子抑製劑、多重標靶性酪氨酸激抑製劑、標靶治療